Fore Biotherapeutics, a precision oncology company dedicated to pioneering the development of cancer therapies, has successfully closed a $67.4M Series d funding round. The company specifically targets patients with unaddressed mutations across well-established oncology targets, aiming to provide solutions where current treatments may fall short.
This significant capital injection will further empower Fore Biotherapeutics in its deeply rooted mission of science and innovation, driving forward its vision to compassionately contribute to solving cancer for those patients in need.
